Latest filingSep 02, 2026Most recent Form 4
ACRV
Acrivon Therapeutics, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/03 to 09/03. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$3.70M7 sells
Net open-market-$3.70M7 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period9transactions
- S · Open-market sells · dominant7 · 78%
- A · Grants / awards2 · 22%
Activity by reported role
A joint filing can contribute to multiple roles12transactions
- EBO · dominant3 · 25%
- PRES3 · 25%
- CBO2 · 17%
- CAO1 · 8%
- CDO1 · 8%
- CLO1 · 8%
- COO1 · 8%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (7)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeBlume-Jensen PeterCommon Stock · Direct
2,230,052Aug 25, 2026
Masson KristinaCommon Stock · Direct
2,230,052Aug 25, 2026
Blume-Jensen PeterCommon Stock · Indirect · See Footnote
385,859Aug 18, 2026
Masson KristinaCommon Stock · Indirect · See Footnote
385,859Aug 18, 2026
Devroe EricCommon Stock · Direct
146,349Aug 18, 2026
Gamelin ErickCommon Stock · Direct
52,592Aug 18, 2026
Miller MaryCommon Stock · Direct
82,009Aug 18, 2026
Peterson KatharineCommon Stock · Direct
18,033Aug 18, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 03 → Sep 03
LessMore
Top insiders
By absolute net value across the selected period- BP-$3.4k
- DE-$1.2k
- GE-$804
- MM-$372
- PK-$203
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
ACRV transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| ACRV | Levin Michaela | CBO | grant | 130k | $0 | A | — | 0.0% | 09/02 | 08/31 |
| ACRV | Levin Michaela | CBO | grant | 30.0k | $0 | A | — | 0.0% | 09/02 | 08/31 |
| ACRV | Peterson Katharine | CAO | sale | 101 | -$20.3k | S | −6.4% | 08/20 | 08/18 | |
| ACRV | Miller Mary | CLO | sale | 185 | -$37.1k | S | −6.4% | 08/20 | 08/18 | |
| ACRV | Gamelin Erick | CDO | sale | 400 | -$80.4k | S | −6.4% | 08/20 | 08/18 | |
| ACRV | Devroe Eric | COO | sale | 604 | -$121k | S | −6.4% | 08/20 | 08/18 | |
| ACRV | Blume-Jensen Peter | PRES | sale | 484 | -$97.2k | S | — | −6.4% | 08/20 | 08/18 |
| ACRV | Blume-Jensen Peter | PRES | sale | 1.22k | -$247k | S | −6.4% | 08/20 | 08/18 |
Acrivon Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Acrivon Therapeutics, Inc.?
Levin Michaela, Blume-Jensen Peter, Masson Kristina, Peterson Katharine, Miller Mary, Gamelin Erick, Devroe Eric.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Blume-Jensen Peter reported a sale on Aug 25, 2026 valued at $3.09M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $37,005.06. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.